NASDAQ:ZFGN - Zafgen Stock Price, Forecast & News

$1.22

-0.07 (-5.43 %)

(As of 01/19/2020 03:57 PM ET)

Add

Compare

Today's Range

$1.16

Now: $1.22▼

$1.30

50-Day Range

$0.71

MA: $1.00▼

$1.48

52-Week Range

$0.62

Now: $1.22▼

$5.45

Volume138,513 shs

Average Volume883,312 shs

Market Capitalization$45.59 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.38

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ZFGN

Previous Symbol

CUSIPN/A

CIK1374690

Webhttp://www.zafgen.com/

Phone617-622-4003

Debt

Debt-to-Equity Ratio0.28

Current Ratio5.11

Quick Ratio5.11

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.53 per share

Price / Book0.48

Profitability

EPS (Most Recent Fiscal Year)($1.90)

Net Income$-61,370,000.00

Net MarginsN/A

Return on Equity-63.33%

Return on Assets-45.44%

Miscellaneous

Employees38

Outstanding Shares37,370,000

Market Cap$45.59 million

Next Earnings Date3/9/2020 (Estimated)

OptionableOptionable

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

Official tax return reveals how one trader nabbed annual gains of 228%, 309% and 339%. His tax return was released online, exposing this simple trading technique used to pocket nearly half a million in profits.

Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.03. View Zafgen's Earnings History.

When is Zafgen's next earnings date?

Zafgen is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Zafgen.

What price target have analysts set for ZFGN?

7 Wall Street analysts have issued twelve-month target prices for Zafgen's stock. Their forecasts range from $0.78 to $17.00. On average, they anticipate Zafgen's share price to reach $7.06 in the next year. This suggests a possible upside of 478.7% from the stock's current price. View Analyst Price Targets for Zafgen.

What is the consensus analysts' recommendation for Zafgen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zafgen.

Has Zafgen been receiving favorable news coverage?

Headlines about ZFGN stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zafgen earned a news impact score of -1.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Zafgen.

Are investors shorting Zafgen?

Zafgen saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 520,800 shares, a decline of 9.8% from the December 15th total of 577,500 shares. Based on an average daily trading volume, of 687,800 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.6% of the shares of the company are short sold. View Zafgen's Current Options Chain.

Who are some of Zafgen's key competitors?

Some companies that are related to Zafgen include Arbutus Biopharma (ABUS), Monopar Therapeutics (MNPR), Five Prime Therapeutics (FPRX), Aravive (ARAV), Nature's Sunshine Products (NATR), Ovid Therapeutics (OVID), Obseva (OBSV), Arcturus Therapeutics (ARCT), Mustang Bio (MBIO), Harrow Health (HROW), Aldeyra Therapeutics (ALDX), Akorn (AKRX), Agile Therapeutics (AGRX), Spero Therapeutics (SPRO) and PhaseBio Pharmaceuticals (PHAS).

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), TG Therapeutics (TGTX), BlackRock (BLK), Micron Technology (MU), Energy Transfer LP Unit (ET), Fate Therapeutics (FATE), SCYNEXIS (SCYX), Esperion Therapeutics (ESPR) and Lexicon Pharmaceuticals (LXRX).

Who are Zafgen's key executives?

Zafgen's management team includes the folowing people:

Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

Who are Zafgen's major shareholders?

Zafgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.23%). View Institutional Ownership Trends for Zafgen.

Which institutional investors are selling Zafgen stock?

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Zafgen.

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $1.22.

How big of a company is Zafgen?

Zafgen has a market capitalization of $45.59 million. The biopharmaceutical company earns $-61,370,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Zafgen employs 38 workers across the globe.View Additional Information About Zafgen.

What is Zafgen's official website?

The official website for Zafgen is http://www.zafgen.com/.

How can I contact Zafgen?

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]

MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		333 (Vote Outperform)
Underperform Votes:		305 (Vote Underperform)
Total Votes:		638

MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe ZFGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: Understanding Market Liquidity

Your Ultimate Investing Toolkit

Just $1.00 for your first month.